Global Blood Therapeutics Inc (GBT) reported quarterly earnings results on Thursday, May-12-2016. The company reported $-0.56 earnings per share for the quarter, missing the analyst consensus estimate by $-0.08. Analysts had a consensus of $-0.48. During the same quarter in the previous year, the company posted $-4.22 EPS.
Many Wall Street Analysts have commented on Global Blood Therapeutics Inc. Shares were Reiterated by Wedbush on Mar 2, 2016 to “Outperform” and Lowered the Price Target to $ 66 from a previous price target of $94 .
In a different news, on Mar 14, 2016, Jung Choi (officer ) purchased 25,000 shares at $20.00 per share price. According to the SEC, on Jan 8, 2016, John Schembri (officer ) purchased 1,500 shares at $21.18 per share price. On Jan 7, 2016, Mark L Perry (director) purchased 5,000 shares at $20.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.